Our story

Flerie develops companies that are built on scientific innovation, driven by the purpose of addressing unmet medical needs and tackling global healthcare challenges

Flerie Invest was established in 2011 by Thomas Eldered, who co-founded and built one of the global top five drug manufacturers, Recipharm. Building on Recipharm’s success and driven by the desire to continue breaking new ground in life sciences, Dr Carl-Johan Spak, now Senior Advisor, and Thomas laid the foundation for Flerie’s evergreen strategy and oversaw the early investments.

In 2017, while still serving as CEO of one of the portfolio companies, Dr Ted Fjällman launched ‘Flerie’n’Peers’ to foster collaboration and knowledge-sharing among Flerie’s portfolio CEOs.  Ted formally joined Flerie Invest as a Venture Partner in 2018 and started laying the foundation, creating the structure and method of working for what would eventually become Flerie AB (publ). He later assumed the role of CEO, continuing to build the team.

Cormorant Pharmaceuticals was sold to Bristol Myers Squibb in 2016 for up to $520 million. Flerie also divested Cobra Biologics to Cognate Bioservices in early 2020 – which enabled further investments

By the end of 2022 the portfolio had expanded to over 30 investments in Europe, Israel, and the US. This major capital deployment was made possible following the divestment of Thomas’ stake in Recipharm in 2021 in one of the largest take-privates in Europe that year. The board was strengthened in early 2023 with seasoned experts Cecilia Edström, Anders Ekblom, and Jenni Nordborg.

Going public was the final step in Flerie’s strategic plan, and in 2024, a reverse merger presented an opportunity too good to pass. In June 2024, Flerie officially listed on Nasdaq Stockholm under the ticker “FLERIE,” offering the public a chance to join the journey. With a strengthened position and new capital raised through a share issue, Flerie is poised for continued growth and success.

Today, the core team of nine is based in Sweden, UK, Switzerland, with easy access to many of the highest performing biotech and pharma ecosystems in the world. All team members have operational experience running life science businesses themselves and can furthermore draw upon many experts and key opinion leaders for due diligence and development needs.

Operational experience, broad networks and international access to the highest performing biotech and pharma ecosystems

Flerie also syndicates with investors from Europe, North America, the Middle East and Asia to actively build product development and commercial growth companies operating primarily in the drug development as well as in the related device and service spaces. The current portfolio spans a diverse array of fields, including immuno-oncology, metabolic diseases, biologics development and manufacturing, and even a cleantech company – each with the potential to make a meaningful and tangible impact on health and wellbeing in society.